1. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development
    Cancer Epidemiol Biomarkers Prev 19: 2611-2622
    Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O ’Loughlin M, Ryan NK, Raymond WA, Horvath LG Kench JG, Stricker P, Marshall VR, Sutherland R L, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Horsfall DJ, Tilley WD and Ricciardelli C (2010).
  2. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer
    British Journal of Cancer (2012)106, 638-645
    King MT, Viney R, Smith DP,Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armb BK
  3. The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy
    BJU Int. 2012 Feb; 109(4): 533-8
    Moore BM, Savdie R, Pebenito RA, Haynes AM, Matthews J, Delprado W, Rasiah KK, Stricker P
  4. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases
    Eur Urol. 2014 Mar;65(3):521-31
    Thompson J, Egger S, Bohn M, Haynes A-M, Matthews J, Rasiah K, Stricker P
  5. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer
    2016 May;195(5):1428-35
    Thompson JE , van Leeuwen PJ , Moses D , Shnier R , Brenner P , Delprado W , Pulbrook M , Bohm M , Haynes A, Hayen A, Stricker P
  6. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy
    BJU Int. 2016 Jan;117(1):48-54
    Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker P
  7. Prospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy
    J Nucl Med. 2015 Aug;56(8):1185-90
    Morigi J J, Stricker S, van Leeuwen P, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L and Louise Emmett L
  8. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer
    BJU Int. 2017 Feb;119(2):209-215
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker P
  9. Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve—Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases
    Eur Urol. 2018 May;73(5):664-671.
    James E. Thompson'Correspondence information about the author James E. ThompsonEmail the author James E. Thompson, Sam Egger, Maret Böhm, Amila R. Siriwardana, Anne-Maree Haynes, Jayne Matthews, Matthijs J. Scheltema, Phillip D. Stricker
  10. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy
    World J Urol. 2018 Mar 28.
    Matthijs J. Scheltema, John I. Chang, Maret Böhm, Willemien van den Bos, Alexandar Blazevsk, Ilan Gielchinsky, Anton M. F. Kalsbeek, Pim J. van Leeuwen, Tuan V. Nguyen, Theo M. de Reijke, Amila R. Siriwardana, James E. Thompson, Jean J. de la Rosette, Phillip D. Stricker
  11. A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy
    BJU Int. 2017 Dec;120(6):774-781.
    Pim J. van Leeuwen, Andrew Hayen, James E. Thompson, Daniel Moses, Ron Shnier, Maret Böhm, Magdaline Abuodha, Anne‐Maree Haynes, Francis Ting, Jelle Barentsz, Monique Roobol, Justin Vass, Krishan Rasiah, Warick Delprado, Phillip D Stricker
  12.  Treatment outcomes from 68 GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET
    J Nucl Med. 2017 Dec;58(12):1972-1976.
    Louise Emmett1, Pim J. van Leeuwen, Rohan Nandurkar, Matthijs J. Scheltema, Thomas Cusick, George Hruby, Andrew Kneebone, Thomas Eade, Gerald Fogarty, Raj Jagavkar, Quoc Nguyen, Bao Ho, Anthony M. Joshua and Phillip Stricker
  13. Imaging: MRI improves cost and accuracy of prostate cancer biopsy
    Nat Rev Urol. 2018 Jan;15(1):6-8.
    James Thompson & Phillip Stricker
  14. 3-year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial.
    J Nucl Med. 2019
    Emmett, L., R. Tang, R. H. Nandurkar, G. Hruby, P. J. Roach, J. A. Watts, T. Cusick, A. Kneebone, B. Ho, L. Chan, P. van Leeuwen, M. Scheltema, A. Nguyen, C. Yin, A. Scott, C. Tang, M. McCarthy, K. Fullard, M. Roberts, R. Francis and P. Stricker
  15. p53 nuclear accumulation as an early indicator of lethal prostate cancer
    Br J Cancer 2019. 121 (7): 578 -583
    Quinn, D. I., P. D. Stricker, J. G. Kench, J. Grogan, A. M. Haynes, S. M. Henshall, J. J. Grygiel, W. Delprado, J. J. Turner, L. G. Horvath and K. L. Mahon.
  16. Metagenomic analysis reveals a rich bacterial content in high- risk prostate tumors from African men.
    Prostate. 2019. 79 (15): 1731 – 1738
    Feng, Y., W. Jaratlerdsiri, S. M. Patrick, R. J. Lyons, A. M. Haynes, C. C. Collins, P. D. Stricker, M. S. R. Bornman and V. M. Hayes
  17. The MRI in Active Surveillance (MRIAS); Trial: Use of Baseline mpMRI and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    Journal of Urology. 2020.
    Amin, A., M. J. Scheltema, R. Shnier, A. Blazevski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. v. Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson
  18. Focal irreversible electroporation as primary treatment for localized prostate cancer
    BJU Int, 121: 716-24.
    van den Bos,W., Scheltema, M. J., Siriwardana, A. R., Kalsbeek A. M. F., Thompson, J. E., Ting, F., Böhm, M., Haynes, A. M., Shnier, R., Delprado, W., Stricker, P. D.
  19. Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive High-Risk Prostate Cancer.
    Cancer Res, Published Online September 14, 2018.
    Jaratlerdsiri, W., Chan, E. K. F., Gong, T., Petersen, D.C., Kalsbeek, A. M. F., Venter, P. A., Stricker, P. D., Bornman, M. S. R., Hayes, V. M.